One Stop Shop for All Your Market Research Reports

Global Recombinant Human EGF Market Size, Status and Forecast 2021-2027

Human EGF is a 6-kDa protein with 53 amino acid residues and three intramolecular disulfide bonds. EGF binds to the epidermal growth factor receptor. Initially, human EGF was known as urogastrone. This report studies the Recombinant Human EGF (Epidermal Growth Factor) obtained by recombinant protein. EGF acts by binding with high affinity to epidermal growth factor receptor (EGFR) on the cell surface. This stimulates ligand-induced dimerization, activating the intrinsic protein-tyrosine kinase activity of the receptor. The tyrosine kinase activity, in turn, initiates a signal transduction cascade that results in a variety of biochemical changes within the cell - a rise in intracellular calcium levels, increased glycolysis and protein synthesis, and increases in the expression of certain genes including the gene for EGFR - that ultimately lead to DNA synthesis and cell proliferation. Market Analysis and Insights: Global Recombinant Human EGF Market The global Recombinant Human EGF market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Recombinant Human EGF market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Recombinant Human EGF market in terms of revenue. On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Recombinant Human EGF market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Recombinant Human EGF market. Global Recombinant Human EGF Scope and Market Size Recombinant Human EGF market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Human EGF market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027. Segment by Type ?98% SDS-PAGE 95%-98% SDS-PAGE <95% SDS-PAGE Segment by Application Scientific Research Medical Drug Others By Region North America U.S. Canada Europe Germany France U.K. Italy Russia Nordic Rest of Europe Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia Latin America Mexico Brazil Rest of Latin America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA By Company FUJIFILM Irvine Scientific PeproTech, Inc R&D Systems (Bio-Techne) Miltenyi Biotec Thermo Fisher Scientific Abcam PLC BioLegend Way STEMCELL Technologies Eurofins DiscoverX RayBiotech, Inc Prospec-Tany Tonbo Biosciences EnQuire Bio ScienCell Research Laboratories BioVision, Inc Abm Inc Cell Guidance Systems Creative BioMart Sino Biological Cell Sciences Axol Bioscience
1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Recombinant Human EGF Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 ?98% SDS-PAGE 1.2.3 95%-98% SDS-PAGE 1.2.4 <95% SDS-PAGE 1.3 Market by Application 1.3.1 Global Recombinant Human EGF Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Scientific Research 1.3.3 Medical D
Inquiry Before Buying

Request Sample

Share This Report

Our Clients

Payment Mode
Single User US $ 3900
Multi User US $5850
Corporate User US $7800
About this Report
Report ID 456492
Category
  • Healthcare
Published on 17-Dec-21
Number of Pages 158
Publisher Name QY Research
Editor Rating
★★★★★
★★★★★
(60)